drugset
drugset / Trial / NCT05277922

Effect of C21 on Forearm Blood Flow

NCT05277922 ↗

Phase 1 Completed 5 enrolled Vicore Pharma AB CTC Clinical Trial Consultants AB · collab
Non-randomizedSingle-groupOpen-labelScreening

Summary

The purpose of this study is to assess the effect of C21 on forearm blood flow by use of strain-gauge venous occlusion plethysmography.

Timeline

Start
2022-04-28
Primary completion
2022-05-11
Completion
2022-05-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Buloxibutid Small molecule 15 ug Other
Subject Buloxibutid Small molecule 50 ug Other
Subject Buloxibutid Small molecule 150 ug Other
Subject Buloxibutid Small molecule 500 ug Other
Subject Buloxibutid Small molecule 1000 ug Other
Subject Sodium Nitroprusside Unknown 4 ug Other
Subject Sodium Nitroprusside Unknown 8 ug Other
Subject Sodium Nitroprusside Unknown 16 ug Other

Indications

isoproterenol-mediated vasodilatation